Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Open accessThe DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: An increased level of Lp(a) lipoprotein has been identified as a risk factor for coronary artery disease that is highly heritable. The genetic determinants of the Lp(a) lipoprotein level and their relevance for the risk of coronary disease are incompletely understood. METHODS: We used a novel gene chip containing 48,742 single-nucleotide polymorphisms (SNPs) in 2100 candidate genes to test for associations in 3145 case subjects with coronary disease and 3352 control subjects. Replication was tested in three independent populations involving 4846 additional case subjects with coronary disease and 4594 control subjects. RESULTS: Three chromosomal regions (6q26-27, 9p21, and 1p13) were strongly associated with the risk of coronary disease. The LPA locus on 6q26-27 encoding Lp(a) lipoprotein had the strongest association. We identified a common variant (rs10455872) at the LPA locus with an odds ratio for coronary disease of 1.70 (95% confidence interval [CI], 1.49 to 1.95) and another independent variant (rs3798220) with an odds ratio of 1.92 (95% CI, 1.48 to 2.49). Both variants were strongly associated with an increased level of Lp(a) lipoprotein, a reduced copy number in LPA (which determines the number of kringle IV-type 2 repeats), and a small Lp(a) lipoprotein size. Replication studies confirmed the effects of both variants on the Lp(a) lipoprotein level and the risk of coronary disease. A meta-analysis showed that with a genotype score involving both LPA SNPs, the odds ratios for coronary disease were 1.51 (95% CI, 1.38 to 1.66) for one variant and 2.57 (95% CI, 1.80 to 3.67) for two or more variants. After adjustment for the Lp(a) lipoprotein level, the association between the LPA genotype score and the risk of coronary disease was abolished. CONCLUSIONS: We identified two LPA variants that were strongly associated with both an increased level of Lp(a) lipoprotein and an increased risk of coronary disease. Our findings provide support for a causal role of Lp(a) lipoprotein in coronary disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consequently, genetic studies found a causal link between elevated Lp(a) levels and a higher risk for CVD diseases,[184–189] and vice versa [190].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [185]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“[Statement]Hyper-Lp(a)-lipoproteinemia is a risk factor for ASCVD. (Evidence level: E-1a)”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [227]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“We found the association between LDLR genotype and Lp(a) levels remained significant after accounting for the rs10455872 genotype that tags a narrower range of LPA alleles10, but we could not directly assess LPA KIV2 copy number variants in the UKBB cohort to assess for a difference between groups.”
From Functional interrogation of cellular Lp(a) uptake by genome-scale CRISPR screening (2025) · cites this paper as [10]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Multiple genome-wide association studies (GWAS) did not find an association between Lp(a) levels and common variants at the LDLR locus10,46,47, but a recent GWAS of 371,212 individuals in the UK Biobank did48.”
From Functional interrogation of cellular Lp(a) uptake by genome-scale CRISPR screening (2025) · cites this paper as [10]
Experimental — accuracy not yet measuredIn the citing paper
“Higher plasma Lp(a) concentrations are associated with an increased risk of ASCVD, but it appears to be a much weaker risk factor for most people than LDL-C [72,73].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [73]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls
The Wellcome Trust Case Control Consortium, Management Committee, Burton, P. R., Clayton, D. G., Cardon, L. R., Craddock, N., Deloukas, P., Duncanson, A., Kwiatkowski, D. P., McCarthy, M. I., et al. (2007) · Nature · doi:10.1038/nature05911 · Cited by 9,442
Genomic Control for Association Studies
Devlin, B., & Roeder, K. (1999) · Biometrics · doi:10.1111/j.0006-341x.1999.00997.x · Cited by 3,162
A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants
Scott, L. J., Mohlke, K. L., Bonnycastle, L. L., Willer, C. J., Li, Y., Duren, W. L., Erdos, M. R., Stringham, H. M., Chines, P. S., Jackson, A. U., et al. (2007) · Science · doi:10.1126/science.1142382 · Cited by 2,753
Replication of Genome-Wide Association Signals in UK Samples Reveals Risk Loci for Type 2 Diabetes
Zeggini, E., Weedon, M. N., Lindgren, C. M., Frayling, T. M., Elliott, K. S., Lango, H., Timpson, N. J., Perry, J. R. B., Rayner, N. W., Freathy, R. M., et al. (2007) · Science · doi:10.1126/science.1142364 · Cited by 2,194
Genomewide Association Analysis of Coronary Artery Disease
Samani, N. J., Erdmann, J., Hall, A. S., Hengstenberg, C., Mangino, M., Mayer, B., Dixon, R. J., Meitinger, T., Braund, P., Wichmann, H.-E., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072366 · Cited by 2,044
(2009) · JAMA · doi:10.1001/jama.2009.1063 · Cited by 1,753
A Common Variant on Chromosome 9p21 Affects the Risk of Myocardial Infarction
Helgadottir, A., Thorleifsson, G., Manolescu, A., Gretarsdottir, S., Blondal, T., Jonasdottir, A., Jonasdottir, A., Sigurdsson, A., Baker, A., Palsson, A., et al. (2007) · Science · doi:10.1126/science.1142842 · Cited by 1,594
A Common Allele on Chromosome 9 Associated with Coronary Heart Disease
McPherson, R., Pertsemlidis, A., Kavaslar, N., Stewart, A., Roberts, R., Cox, D. R., Hinds, D. A., Pennacchio, L. A., Tybjaerg-Hansen, A., Folsom, A. R., et al. (2007) · Science · doi:10.1126/science.1142447 · Cited by 1,587
Newly identified loci that influence lipid concentrations and risk of coronary artery disease
Willer, C. J., Sanna, S., Jackson, A. U., Scuteri, A., Bonnycastle, L. L., Clarke, R., Heath, S. C., Timpson, N. J., Najjar, S. S., Stringham, H. M., et al. (2008) · Nature Genetics · doi:10.1038/ng.76 · Cited by 1,585
Self-citationCommon variants at 30 loci contribute to polygenic dyslipidemia
Kathiresan, S., Willer, C. J., Peloso, G. M., Demissie, S., Musunuru, K., Schadt, E. E., Kaplan, L., Bennett, D., Li, Y., Tanaka, T., et al. (2009) · Nature Genetics · doi:10.1038/ng.291 · Cited by 1,364
Self-citation
Research works printed but not linked: 1
- Siekmeier R, 1996, Lab Medizin, 20, 294
Cited by
Items 901–1,000 of 1,004
Ahmad‐Nejad, P., Duda, A., Sucker, A., Werner, M., Bronsert, P., Stickeler, E., Reifenberger, G., Malzkorn, B., Oberländer, M., Habermann, J. K., et al. (2015) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2014-1202 · Cited by 12
Wang, M., Lee-Kim, V. S., Atri, D. S., Elowe, N. H., Yu, J., Garvie, C. W., Won, H., Hadaya, J. E., MacDonald, B. T., Trindade, K., et al. (2021) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.121.003399 · Cited by 12
Loh, W. J., & Watts, G. F. (2022) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000789 · Cited by 12
Babadagli, H. E., Barry, A. R., Thanassoulis, G., & Pearson, G. J. (2023) · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada · doi:10.1177/17151635231164989 · Cited by 12
Primary prevention of cardiovascular disease in women
Gray, M. P., Vogel, B., Mehran, R., Leopold, J. A., & Figtree, G. A. (2024) · Climacteric · doi:10.1080/13697137.2023.2282685 · Cited by 14
“Elevated lipoprotein(a) (Lp(a)) is associated with high burden of atherosclerosis, and can occur independently of elevated LDL cholesterol [73,74].”
BackgroundLipids and Inflammation: Novel Molecular Targets and Therapeutic Implications
Triglia, L. T., Gurgoglione, F. L., Barocelli, F., Bianconcini, M., & Niccoli, G. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673311105240902053715 · Cited by 12
Cardiovascular Aspects of Kidney Disease
Wheeler, D. C., Haynes, R., Landray, M., & Baigent, C. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6193-9.10055-7 · Cited by 14
Clinical utility of evolocumab in the management of hyperlipidemia: patient selection and follow-up
Dixon, D. L., Buckley, L. F., Trankle, C. R., Kadariya, D., & Abbate, A. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s114091 · Cited by 13
“Lipoprotein(a) Lipoprotein(a) (Lp[a]) consists of ApoA, a plasminogen-like protein that may interfere with fibrinolysis covalently bound to the ApoB of an LDL particle, and has been associated with cardiovascular risk.(29) Data from clinical trials of evolocumab monotherapy (MENDEL and MENDEL 2), evolocumab add-on the…”
Sun, D., Zhao, X., Li, S., Zhang, Y., Wu, N. Q., Zhu, C. G., Guo, Y. L., Gao, Y., Qing, P., Liu, G., et al. (2018) · PubMed · doi:10.3967/bes2018.033 · Cited by 12
The Future of Lipid-Lowering Therapy
Zwol, W. H.-V., Rimbert, A., & Kuivenhoven, J. A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8071085 · Cited by 14
Fras, Z. (2019) · The Anatolian Journal of Cardiology · doi:10.14744/anatoljcardiol.2019.56068 · Cited by 13
“causally implicated in the development of CVD (3, 4).”
BackgroundTakahashi, N., Dohi, T., Funamizu, T., Endo, H., Wada, H., Doi, S., Kato, Y., Ogita, M., Okai, I., Iwata, H., et al. (2020) · Journal of Cardiology · doi:10.1016/j.jjcc.2020.01.013 · Cited by 12
Nicholls, S. J., & Bubb, K. J. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01528-w · Cited by 13
Case Studies in Pediatric Lipid Disorders and Their Management
Ashraf, A. P., Sunil, B., Bamba, V., Breidbart, E., Brar, P. C., Chung, S. T., Gupta, A., Khokhar, A., Kumar, S., Lightbourne, M., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab568 · Cited by 12
Lp(a) - an overlooked risk factor
Laffin, L. J., & Nissen, S. E. (2023) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2023.01.003 · Cited by 12
Shiffman, D., Louie, J. Z., Rowland, C. M., Malloy, M. J., Kane, J. P., & Devlin, J. J. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.05.009 · Cited by 13
Ahmadpour, F. (2014) · Journal of Molecular and Genetic Medicine · doi:10.4172/1747-0862.s1-019 · Cited by 16
“It's suggested that some genetic and environmental factors affect the prevalence of lipid abnormalities [75-77].”
BackgroundLipoprotein(a) Removal Still a Mystery
Nestel, P. J. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.011903 · Cited by 12
Lipoprotein(a) and Oxidized Phospholipids
Rader, D. J., & Bajaj, A. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.02.051 · Cited by 12
Rahimi, M., Khanahmad, H., Gharipour, M., Roohafza, H., Dianatkhah, M., Khosravi, E., Sadeghian, L., & Sadeghi, M. (2021) · PubMed Central · doi:10.22122/arya.v17i0.2369 · Cited by 12
Björnson, E., Adiels, M., Borén, J., & Packard, C. J. (2024) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001170 · Cited by 11
Evaluating Pericoronary Adipose Tissue Attenuation to Predict Cardiovascular Events
Nishihara, T., Miyoshi, T., Ejiri, K., Osawa, K., Fuke, S., Seiyama, K., Doi, M., Nakashima, M., Miki, T., & Yuasa, S. (2024) · JACC Asia · doi:10.1016/j.jacasi.2024.09.009 · Cited by 11
Interaction Between Lipoprotein(a) and Other Lipid Molecules: A Review of the Current Literature
Sheashaa, H., Mousa, H., Abbas, M. T., Farina, J., Awad, K., Pereyra, M., Scalia, I. G., Ali, N. B., Javadi, N., Bismee, N. N., et al. (2025) · Biomolecules · doi:10.3390/biom15020162 · Cited by 11
Genetic Determinants of the Familial Hypercholesterolaemia Phenotype
Humphries, S. E., & Futema, M. (2025) · Annals of Human Genetics · doi:10.1111/ahg.12594 · Cited by 11
“An increased concentration of Lp(a) is a well-established independent risk factor for CHD (Nordestgaard and Langsted 2016), and in Mendelian Randomisation studies, SNPs in the LPA region are strongly associated with CHD risk (Clarke et al. 2009).”
Navigating the Landscape of Translational Medicine of Calcific Aortic Valve Disease
Qian, X., Xu, L., Geng, B., Li, F., & Dong, N. (2025) · JACC Asia · doi:10.1016/j.jacasi.2025.01.014 · Cited by 11
Lipoprotein(a) and Venous Thromboembolism: Association, Causality, and Medications
Pfeferman, M. B., Rashedi, S., Lip, G. Y. H., Weber, C., O’Donoghue, M. L., Nissen, S. E., Nicholls, S. J., Natarajan, P., Plutzky, J., Libby, P., et al. (2025) · Thrombosis and Haemostasis · doi:10.1055/a-2674-5114 · Cited by 14
Nordestgaard, A. G., Chasman, D. I., Moorthy, M. V., Kraaijenhof, J. M., Cook, N. R., Lee, I.-M. M., Buring, J. E., & Ridker, P. M. (2026) · JAMA Cardiology · doi:10.1001/jamacardio.2025.5043 · Cited by 11
The evolving role of CETP inhibition: beyond HDL cholesterol
Ray, K. K., & Vallejo‐Vaz, A. J. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60608-0 · Cited by 11
Huang, E., Peng, L., Zheng, J., Wang, D., Tan, X., Yang, Z., Li, X.-M., Wu, Q., Tang, S., Luo, B., et al. (2016) · Journal of Human Genetics · doi:10.1038/jhg.2015.158 · Cited by 11
Salsoso, R., Dalçóquio, T. F., Furtado, R. H. M., Franci, A., Barbosa, C., Genestreti, P., Strunz, C. M. C., Lima, V., Baracioli, L. M., Giugliano, R. P., et al. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01483-y · Cited by 11
Lanjanian, H., Bonab, L. N. H., Akbarzadeh, M., Moazzam‐Jazi, M., Zahedi, A. S., Masjoudi, S., & DANESHPOUR, M. S. (2022) · Biology of Sex Differences · doi:10.1186/s13293-022-00413-7 · Cited by 11
“Moreover, numerous case– control studies have confirmed that hyper-Lp(a) is a risk factor for premature cardiovascular disease [1, 2, 26].”
BackgroundOkada, T., Miyoshi, T., Doi, M., Nosaka, K., Tsushima, R., Ugawa, S., Takagi, W., Sogo, M., Takahashi, M., & Ito, H. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9050153 · Cited by 11
“Mendelian randomization studies have linked genetic variations at the LPA locus to both circulating lipoprotein(a) levels and the risk of cardiovascular disease (CVD), supporting a causal role of lipoprotein(a) in CVD pathogenesis [4,5].”
BackgroundEsau, D., & Abramson, B. L. (2022) · Canadian Family Physician · doi:10.46747/cfp.6809654 · Cited by 12
A New Modality in Dyslipidemia Treatment: Antisense Oligonucleotide Therapy
Kim, K., & Choi, S. H. (2022) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2022.11.3.250 · Cited by 11
Li, C., Wei, M., Mo, L., Velu, P., Prabahar, K., Găman, M., & Chen, M. (2023) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2023.10.020 · Cited by 11
Maloberti, A., Intravaia, R. C. M., Mancusi, C., Cesaro, A., Golia, E., Fucile, I., Coletta, S., Merlini, P. A., Chiara, B. C. D., Bernasconi, D. P., et al. (2023) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-023-00607-z · Cited by 11
“The relationship between Lp(a) and CV events has been well established in epidemiological and GWAS studies [25, 26] and it is considered the strongest single genetic risk factor known for CV diseases [27].”
BackgroundDelgado‐Lista, J., Mostaza, J. M., Arrobas-Velilla, T., Blanco‐Vaca, F., Masana, L., Pedro‐Botet, J., Pérez‐Martínez, P., Civeira, F., Cuende, J. I., Gómez-Barrado, J. J., et al. (2024) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2024.03.002 · Cited by 14
Nakamura, N., Sakai, K., Torii, S., Aoki, Y., Turcotte‐Gosselin, F., Fujinuma, K., Ohwaki, A., Aihara, K., Noda, S., Miyamoto, J., et al. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.08.011 · Cited by 11
Cyclosporin A-Induced Hyperlipidemia
Kockx, M., & Kritharides, L. (2012) · InTech eBooks · doi:10.5772/47866 · Cited by 12
“Plasma Lp(a) levels, and especially certain genetic Lp(a) variants, are independently associated with an increased risk for CVD [28,29].”
BackgroundTherapeutic potential of antisense oligonucleotides for the management of dyslipidemia
Crooke, R. M., & Graham, M. J. (2011) · Clinical Lipidology · doi:10.2217/clp.11.59 · Cited by 11
Recent success in the discovery of coronary artery disease genes
Roberts, R., Chen, L., Wells, G. A., & Stewart, A. F. R. (2011) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y11-041 · Cited by 14
Freudenberg‐Hua, Y., Li, W., Abhyankar, A., Vacic, V., Côrtes, V. R. P., Ben‐Avraham, D., Koppel, J. L., GREENWALD, B. S., Germer, S., Darnell, R. B., et al. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw150 · Cited by 11
“Consistently, the two previously reported risk alleles for coronary artery disease rs10455872 and rs3798220 (51) were observed exclusively in our AD subjects ( n ¼ 5 and 1, respectively) and not among any CEN.”
BackgroundSerum lipoprotein(a) and risk of mortality in patients on peritoneal dialysis
Zhong, Z., Peng, F., Shi, D., Peng, Y., Li, B., Xiao, M., Feng, S., Mao, H., Huang, F., Yang, X., et al. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.01.008 · Cited by 12
The Potential Clinical Benefit of Lowering Lipoprotein(a)
Ference, B. A. (2022) · JAMA · doi:10.1001/jama.2022.5333 · Cited by 11
Joshi, P. H., Rinehart, S. J., Vazquez, G., Qian, Z., Sharma, A., Anderson, H., Murrieta, L., Flockhart, N., Karmpaliotis, D., Kalynych, A. M., et al. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2223-3652.2013.01.02 · Cited by 11
“More recently, several extensive, genome-wide association studies attempted to identify variants in the human genome that carry susceptibility for the development of coronary artery disease (CAD) and cardiovascular events (3-6).”
BackgroundTargeted exonic sequencing of GWAS loci in the high extremes of the plasma lipids distribution
Patel, A. P., Peloso, G. M., Pirruccello, J. P., Johansen, C. T., Dubé, J. B., Larach, D. B., Ban, M. R., Dallinga‐Thie, G. M., Gupta, N., Boehnke, M., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.04.011 · Cited by 11
A rare missense variant in NR1H4 associates with lower cholesterol levels
Deaton, A. M., Sulem, P., Nioi, P., Benónísdóttir, S., Ward, L. D., Davidsson, O. B., Lao, S., Helgadóttir, A., Fan, F., Jensson, B. Ö., et al. (2018) · Communications Biology · doi:10.1038/s42003-018-0015-9 · Cited by 11
Advanced in Molecular Mechanisms of Atherosclerosis: From Lipids to Inflammation
Meiliana, A., Dewi, N. M., & Wijaya, A. (2018) · The Indonesian Biomedical Journal · doi:10.18585/inabj.v10i2.479 · Cited by 14
“(230) Mendelian randomization studies found that genetically elevated Lp(a) results in increased risk of CHD.(231,232) Then, it was suggested that decreasing plasma Lp(a) may have a cardiovascular protective effect.”
BackgroundYou, X.-D., Jin, J., Zhang, H., Guo, N., Hou, B., Guo, Y., Wu, N., Zhu, C., & Li, J. (2019) · Personalized Medicine · doi:10.2217/pme-2018-0127 · Cited by 11
Impact of genetic information on coronary disease risk in Madeira: The GENEMACOR study
Mendonça, M. I., Pereira, A., Monteiro, J. P., Sousa, J., Santos, M., Temtem, M., Borges, S., Henriques, E., Rodrigues, M. F., Sousa, A. C., et al. (2022) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2022.01.009 · Cited by 11
Araújo, B., Arrighini, G. S., Queiroga, F., Mansouri, E. S., Rivera, A., Amador, W. F. O., Queiroz, I., Akabane, M. A. C. C., Consoli, L. N., Sobral, M. V. S., et al. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101303 · Cited by 10
“Elevated Lp(a) is now well-recognized as an independent risk factor for atherosclerotic cardiovascular disease [26].”
Abdalla, H., Mahmoud, A., Khedr, A. E., Farina, J., Scalia, I. G., Abbas, M. T., Awad, K., Ali, N. B., Bismee, N. N., Esfahani, S. A., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011029 · Cited by 10
Kim, B. J., & Kang, J. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.02.007 · Cited by 10
RNA-based drugs: current, imminent and possible therapeutic applications
Torrisi, S. A., Geraci, F., Diolosà, L., Luca, A. D., Falzone, L., Drago, F., Libra, M., & Leggio, G. M. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108958 · Cited by 11
Lipoprotein(a) and Its Role in Peripheral Arterial Disease: A Narrative Review
Mwipatayi, B. P., Dodd, J. E., Bazlee, A. H. A., Stratford, G., Lee, B., Mori, T. A., Watts, G. F., Armari, E., Wong, J., & Schlaich, M. P. (2025) · Vascular Health and Risk Management · doi:10.2147/vhrm.s555127 · Cited by 10
“24, 24–30 Pathogenicity of Lp(a) The role of Lp(a) in PAD is summarized in Table 1, which outlines the principal pathobiological mechanisms involved.”
Síndrome metabólico, lipoproteína(a) y aterosclerosis subclínica en población mexicana
Cardoso-Saldaña, G. C., González-Salazar, M. D. C., Posadas‐Sánchez, R., & Vargas‐Alarcón, G. (2020) · Archivos de cardiología de México · doi:10.24875/acm.20000276 · Cited by 10
Causal associations between disorders of lipoprotein metabolism and ten cardiovascular diseases
Gao, Q., Tan, J., Fan, L., Wang, X., Hua, L., & Cai, J. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1023006 · Cited by 10
“In the past decade, disorders of lipoprotein metabolism have been linked to increased risk of CVDs. Large prospective general population studies have shown that high Lp(a) concentrations increase the risks of CHD (Kamstrup et al., 2008), nonfatalMI, and coronary death (Erqou et al., 2009).”
BackgroundInfluentialRuder, S., Mansfield, B. S., Immelman, A., Varki, N. M., Miu, P., Raal, F. J., & Tsimikas, S. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01720-z · Cited by 11
Efficacy of Diagnostic Testing of Suspected Coronary Artery Disease: A Contemporary Review
Woods, E. A., Bennett, J., Chandrasekhar, S. A., Newman, N. A., Rizwan, A. M., Siddiqui, R., Khan, R., Khawaja, M., & Krittanawong, C. (2024) · Cardiology · doi:10.1159/000539916 · Cited by 12
Apple pectin for the reduction of niacin-induced flushing
Moriarty, P. M., Backes, J. M., Dutton, J.-A., He, J., Ruisinger, J. F., & Schmelzle, K. H. (2012) · Journal of clinical lipidology · doi:10.1016/j.jacl.2012.11.005 · Cited by 10
Fechtel, K., Osterbur, M. L., Kehrer‐Sawatzki, H., Stenson, P. D., & Cooper, D. N. (2011) · Human Genetics · doi:10.1007/s00439-011-0984-y · Cited by 10
“Finally, expansion of Kringle IV domains through partial CNV in LPA (van der Hoek et al. 1993) is associated with a reduced risk of ischemic heart disease (Clarke et al. 2009; reviewed by Kamstrup 2010) indicating a positive attribute associated with an intragenic, partial CNV.”
BackgroundRisk Markers for Atherothrombotic Disease
Ridker, P. M., & Libby, P. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0398-6.00044-5 · Cited by 16
Lipoprotein (a) and coronary heart disease – is there an efficient secondary prevention?
Mellwig, K., Horstkotte, D., & van Buuren, F. (2017) · Clinical Research in Cardiology Supplements · doi:10.1007/s11789-017-0088-x · Cited by 10
“The structure of Lp (a) consisting of the Lp (a)-specific glycoprotein apolipoproteina (APO (a)) implies the pro-atherogenous and pro-thrombogenous characteristics [3] with increased risk of myocardial infarction and heart failure [5].”
Conditional Inference Tree for Multiple Gene-Environment Interactions on Myocardial Infarction
Wu, Z., Su, X., Sheng, H., Chen, Y., Gao, X., Bao, L., & Jin, W. (2017) · Archives of Medical Research · doi:10.1016/j.arcmed.2017.12.001 · Cited by 12
Lipids and Lipoproteins in Risk Prediction
Hadjiphilippou, S., & Ray, K. K. (2018) · Cardiology Clinics · doi:10.1016/j.ccl.2017.12.002 · Cited by 12
Kar, S. (2020) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2020.100581 · Cited by 10
Human gain-of-function MC4R variants show signaling bias and protect against obesity
Lotta, L. A., Mokrosiński, J., Mendes de Oliveira, E., Li, C., Sharp, S. J., Luan, J., Brouwers, B., Ayinampudi, V., Bowker, N., Kerrison, N. D., et al. (2020) · Yearbook of pediatric endocrinology · doi:10.1530/ey.17.11.3 · Cited by 10
Elevated lipoprotein(a) as a predictor for coronary events in older men
Bartoli‐Leonard, F., Turner, M. E., Zimmer, J., Chapurlat, R. D., Pham, T., Aikawa, M., Pradhan, A. D., Szulc, P., & Aïkawa, E. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100242 · Cited by 11
“Previous studies with quintile or quartile stratification of Lp(a) analysis have identified this increased risk (3); however, the application of absolute cutoff values of Lp(a) is useful to support future clinical integration of this measurement.”
BackgroundBhat, K. G., Guleria, V. S., Ratheesh Kumar, J., Rastogi, G., Sharma, V., & Sharma, A. (2022) · PubMed · Cited by 11
Lipoprotein (A) in clinical practice.
Jayasinghe, R., Craig, I. H., & Mohan, R. K. A. (2014) · PubMed · Cited by 10
Effect of Two Lipoprotein (a)-Associated Genetic Variants on Plasminogen Levels and Fibrinolysis
Wang, H., Hong, C. E., Lewis, J. P., Zhu, Y., Wang, X., Chu, X., Backman, J., Hu, Z., Yang, P., Still, C. D., et al. (2016) · G3 Genes Genomes Genetics · doi:10.1534/g3.116.034702 · Cited by 11
“Consistent with previous studies, the plasma Lp(a) levels were significantly higher for carriers of rs3798220 or rs10455872 compared to noncarriers in the OOA subjects (Clarke et al. 2009; Laschkolnig et al. 2014; Lu et al. 2015).”
BackgroundResultInfluentialLikozar, A. R., Blinc, A., Podkrajšek, K. T., & Šebeštjen, M. (2021) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd8120181 · Cited by 10
“showed that increasing numbers of variant alleles were associated with increased risk of future cardiovascular events [4].”
BackgroundMethodInfluentialValue of Genetic Testing for Lipoprotein(a) Variants
Langsted, A., & Nordestgaard, B. G. (2022) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.122.003737 · Cited by 11
McClintick, D. J., Biery, D. W., Berman, A. N., Besser, S. A., Shiyovich, A., Singh, A., Huck, D. M., Weber, B., Cardoso, R. N., Bonaca, M. P., et al. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf475 · Cited by 9
Lipoprotein(a) in Cardiovascular Diseases and Emerging Therapeutic Strategies
Al‐Horani, R. A., Selico-Dunn, A. C., & Smith, E. L. S. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07810-1 · Cited by 11
Diabetes Mellitus and Lipoprotein(a): A Determinant Interaction in Micro- and Macrovascular Damage
Polo-Barranco, A., Rebolledo-Maldonado, C., Esquiaqui-Rangel, V., Nuñez-Mejia, A., Rambal-Torres, J., Barraza-Ahumada, V., Vargas-Cantillo, S., la Cruz, W. B.-D., Liñán-Martínez, V., Rada-Obeso, V., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311427 · Cited by 9
“In this scenario, Lp(a) is determined by the genetics of the LPA gene, specifically in three chromosomal regions (6q26-27, 9p21, and 1p13) and in two SNPs (rs10455872 and rs3798220) that were strongly related to coronary artery disease [155].”
Danilov, A., Luciano, P. D., Yuan, Y., Gomes, D. D. O., López, J. A. G., Kent, S. T., Booth, J. N., Slipczuk, L. N., Martinez, C. A., Kaplan, R. C., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.09.1605 · Cited by 9
Presumed Mechanisms Underlying Lipoprotein(a)-caused Atherosclerosis
Filtz, A., Slipczuk, L. N., & Gulati, M. (2026) · European Cardiology Review · doi:10.15420/ecr.2025.66 · Cited by 9
“15,16 17–19 They also show a higher propensity to deposit within the arterial wall.”
No small task: therapeutic targeting of Lp(a) for cardiovascular disease
Feinberg, M. W. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31329-0 · Cited by 10
Zhang, Z., Dai, W., Zhu, W., Rodriguez, M., Lund, H., Xia, Y., Chen, Y., Rau, M. J., Schneider, E. A., Graham, M. B., et al. (2023) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2023.102164 · Cited by 10
“Mendelian randomization analyses further revealed that people with genetic variants associated with elevated Lp(a) had increased CVD risk [84,85].”
InfluentialAfzal, Z., Cao, H., Chaudhary, M. A., Chigurupati, H. D., Neppala, S., Alruwaili, W., Awad, M. A., Sandesara, D., Siddique, M., Farman, A., et al. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102586 · Cited by 10
Delgado‐Lista, J., Mostaza, J. M., Arrobas-Velilla, T., Blanco‐Vaca, F., Masana, L., Pedro‐Botet, J., Pérez‐Martínez, P., Civeira, F., Cuende, J. I., Gómez-Barrado, J. J., et al. (2024) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2024.07.008 · Cited by 24
Zhu, Y., Chen, S., Chen, Z., Wang, Y., Fu, G., & Zhang, W. (2024) · Renal Failure · doi:10.1080/0886022x.2024.2383727 · Cited by 9
“It was well known that elevated Lp(a) was associated with an increased risk of coronary heart disease [23,36].”
BackgroundMethodInfluentialFeng, Y., Zhang, S., Li, H., Li, H., Dong, R., Zhu, S., & Zhou, Y. (2024) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.25120 · Cited by 9
A genetic variant near the PMAIP1/Noxa gene is associated with increased bleomycin sensitivity
Gu, J. H., Ye, Y., Spitz, M. R., Lin, J. M., Kiemeney, L. A. L. M., Xing, J., Hildebrandt, M. A. T., Hong, W. K., Amos, C. I., & Wu, X. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq509 · Cited by 10
Montecucco, F., Carbone, F., Dini, F. L., Fiúza, M., Pinto, F. J., Martelli, A., Palombo, D., Sambuceti, G., Mach, F., & Caterina, R. D. (2014) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2014.09.015 · Cited by 9
“[22] 2009 Case–control (3145 CAD patients and 3352 control,”
Use of Pharmacogenetic Information in the Treatment of Cardiovascular Disease
Friede, K. A., Li, J. H., & Voora, D. (2016) · Clinical Chemistry · doi:10.1373/clinchem.2016.255232 · Cited by 9
Reduction of cardiovascular risk in subjects with high lipoprotein (a) levels
Malaguarnera, G., Latteri, S., Catania, V. E., & Malaguarnera, M. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.08.67 · Cited by 10
“The rs 3798220 and rs 10455872 single nucleotide polymorphisms (SNPs), which were most strongly associated with Lp(a) levels, were most strongly associated with coronary disease risk (13).”
BackgroundConsiderations for routinely testing for high lipoprotein(a)
Nurmohamed, N. S., Moriarty, P. M., & Stroes, E. S. G. (2022) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000838 · Cited by 11
Study on the relationship between lipoprotein (a) and diabetic kidney disease
Wang, A., Zhang, S., Li, Y., Zhu, F., & Xie, B. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108378 · Cited by 9
Girard, A. S., Gaillard, E., Puri, R., Capoulade, R., Chan, K. L., Paulin, A., Manikpurage, H. D., Dumesnil, J. G., Tam, J. W., Teo, K. K., et al. (2023) · European Heart Journal Open · doi:10.1093/ehjopen/oead032 · Cited by 9
Targeting Lipoprotein (a): an Evolving Therapeutic Landscape
Man, L. C., Kelly, E. M., & Duffy, D. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0502-0 · Cited by 10
Enkhmaa, B., Abbuthalha, A., Anuurad, E., Zhang, W., Tarantal, A. F., & Berglund, L. (2015) · Journal of Medical Primatology · doi:10.1111/jmp.12160 · Cited by 9
Cardiovascular Disease Risk Assessment: Review of Established and Newer Modalities
Tehrani, D. M., & Wong, N. D. (2015) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-015-0420-z · Cited by 10
Experimental Biology for the Identification of Causal Pathways in Atherosclerosis
Guo, Y., Garcia-Barrio, M. T., Wang, L., & Chen, Y. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6644-7 · Cited by 9
Genetics of the acute coronary syndrome
Franchini, M. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.02.12 · Cited by 10
Hyperlipoproteinaemia(a) – apheresis and emerging therapies
Vogt, A. (2017) · Clinical Research in Cardiology Supplements · doi:10.1007/s11789-017-0083-2 · Cited by 9
Clinical Application of Genetic Testing in Heart Failure
Morales, A., & Hershberger, R. E. (2017) · Current Heart Failure Reports · doi:10.1007/s11897-017-0366-4 · Cited by 10
Tüten, A., Gungor, Z., Ekmekçi, H., Ekmekçi, Ö. B., Kücür, M., Yılmaz, N., Donma, O., Sönmez, H. A., Açıkgöz, A. S., & Madazlı, R. (2019) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2019.1622667 · Cited by 11
Afanasieva, O. I., & Pokrovsky, S. N. (2019) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2019-5-101-108 · Cited by 10
Metadata
- Authors
- Clarke, R., Peden, J. F., Hopewell, J. C., Kyriakou, T., Goel, A., Heath, S. C., Parish, S., Barlera, S., Franzosi, M. G., Rust, S., Bennett, D., Silveira, A., Malarstig, A., Green, F. R., Lathrop, M., Gigante, B., Leander, K., de Faire, U., Seedorf, U., Hamsten, A., Collins, R., Watkins, H., & Farrall, M.
- Affiliations
- University of Oxford (GB)
- Centre for Human Genetics (GB)
- Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR)
- Mario Negri Institute for Pharmacological Research (IT)
- University of Münster (DE)
- University of Surrey (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-12-24
- Volume
- 361
- Issue
- 26
- Pages
- 2518-2528
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2098230963
- Cited by
- 1,671
- References
- 40
- Citations by year
- 2026: 129 · 2025: 134 · 2024: 121 · 2023: 124 · 2022: 133 · 2021: 103 · 2020: 101 · 2019: 96 · 2018: 75 · 2017: 90 · 2016: 103 · 2015: 90 · 2014: 82 · 2013: 73 · 2012: 88
- FWCI
- 73.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Surrey Research Insight Open Access (The University of Surrey) (submittedVersion)
- Funders
- Wellcome Trust
- British Heart Foundation
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Keywords
- coronary artery disease, LPA gene, single nucleotide polymorphisms, rs10455872, rs3798220, genetic association, 9p21
- MeSH terms
- Coronary Disease, Genetic Markers, Genotype, Humans, Myocardial Infarction, Regression Analysis, Risk Factors, Likelihood Functions, Case-Control Studies, Lipoprotein(a), Kringles, Genetic Predisposition to Disease, Oligonucleotide Array Sequence Analysis, Polymorphism, Single Nucleotide, Genome-Wide Association Study
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.